138 related articles for article (PubMed ID: 31402146)
1. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction.
Hill LG; Evoy KE; Reveles KR
J Am Pharm Assoc (2003); 2019; 59(6):779-782. PubMed ID: 31402146
[TBL] [Abstract][Full Text] [Related]
2. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
Stopka TJ; Donahue A; Hutcheson M; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
[TBL] [Abstract][Full Text] [Related]
3. Strategies and policies to address the opioid epidemic: A case study of Ohio.
Penm J; MacKinnon NJ; Boone JM; Ciaccia A; McNamee C; Winstanley EL
J Am Pharm Assoc (2003); 2017; 57(2S):S148-S153. PubMed ID: 28189539
[TBL] [Abstract][Full Text] [Related]
4. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
[TBL] [Abstract][Full Text] [Related]
5. State legal innovations to encourage naloxone dispensing.
Davis C; Carr D
J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
[TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of clinical pharmacists on naloxone coprescribing in the primary care setting.
Watson A; Guay K; Ribis D
Am J Health Syst Pharm; 2020 Mar; 77(7):568-573. PubMed ID: 32207821
[TBL] [Abstract][Full Text] [Related]
7. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
8. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
Palmer E; Hart S; Freeman PR
J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
[TBL] [Abstract][Full Text] [Related]
9. A Laboratory Session to Prepare Pharmacy Students to Manage the Opioid Crisis Situation.
Donohoe KL; Raghavan A; Tran TT; Alotaibi FM; Powers KE; Frankart LM
Am J Pharm Educ; 2019 Sep; 83(7):6988. PubMed ID: 31619820
[No Abstract] [Full Text] [Related]
10. Naloxone for Opioid Overdose and the Role of the Pharmacist.
Toderika Y; Williams S
Consult Pharm; 2018 Feb; 33(2):98-104. PubMed ID: 29409576
[TBL] [Abstract][Full Text] [Related]
11. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
12. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
[TBL] [Abstract][Full Text] [Related]
13. Implementation of a naloxone dispensing program in a grocery store-based community pharmacy.
Wilkerson DM; Groves BK; Mehta BH
Am J Health Syst Pharm; 2020 Mar; 77(7):511-514. PubMed ID: 32086505
[No Abstract] [Full Text] [Related]
14. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
[TBL] [Abstract][Full Text] [Related]
15. The pharmacist role in the development and implementation of a naloxone prescription program in Alabama.
Wulz JL; Sung H; Dugan BD; Wensel TM; Lander R; Manzella B
J Am Pharm Assoc (2003); 2017; 57(2S):S141-S147. PubMed ID: 28209338
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
Cariveau D; Fay AE; Baker D; Fagan EB; Wilson CG
J Am Pharm Assoc (2003); 2019; 59(6):867-871. PubMed ID: 31466899
[TBL] [Abstract][Full Text] [Related]
17. NEXT Harm Reduction: An Online, Mail-Based Naloxone Distribution and Harm-Reduction Program.
Yang C; Favaro J; Meacham MC
Am J Public Health; 2021 Apr; 111(4):667-671. PubMed ID: 33600254
[TBL] [Abstract][Full Text] [Related]
18. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
19. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
[TBL] [Abstract][Full Text] [Related]
20. The opioid crisis: Origins, trends, policies, and the roles of pharmacists.
Chisholm-Burns MA; Spivey CA; Sherwin E; Wheeler J; Hohmeier K
Am J Health Syst Pharm; 2019 Mar; 76(7):424-435. PubMed ID: 31361827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]